Related to Abbott Pays Galapagos $150M Up Front for Phase II-Stage Rheumatoid Arthritis Drug

• Abbott and EpiTherapeutics Ally to Develop Epigenetic Cancer Drugs
  
• Merck & Co. Axes Partnership with Galapagos
  
• Abbott to Use Seattle Genetics’ Antibody-Drug Conjugate Platform for $8M Up Front
  
• Abbott to Distribute Biofortuna’s Freeze-Dried HLA-Typing PCR Kits
  
• NovAliX Inks SPR-Based Fragment Screening Deal for Lead Discovery with Galapagos
  
• Servier and Galapagos Embark on Cancer Drug Alliance Valued at €260M
  
• Neurocrine Wins $20M from Abbott Related to Elagolix for Endometriosis
  
• Phase III Trial Confirms Benefits of Abbott’s Humira Against Nonradiographic Axial Spondyloarthritis
  
• Abbott, GSK Add Immunotherapies to Companion Dx Partnership
  
• Abbott Pays Reata $400M in Expanded Antioxidant Inflammation Modulator Deal
  
• Abbott, Emergent Terminate Co-Development Deal for B-Cell Cancers
  
• Private-Public Partnership Focusing on Neglected Tropical Diseases Established
  
• Merck & Co. Signs Up Abbott to Develop a Companion Diagnostic for Anticancer Candidate
  
• Abbott Nabs Distribution Rights to Biofortuna’s Freeze-Dried HLA Typing Kits
  
• Abbott Pays Action $110M for Global Rights to Phase II-Stage Acute Kidney Injury Drug
  
• IntelligentMDx Wins CE Mark for Group B Strep Assay on Abbott m2000 Instrument
  
• Galapagos and Roche Call It Quits
  
• Galapagos Earns $4.7M in RA Alliance with Janssen
  
• Abbott Pays Biotest $85M Up Front in Deal for Phase II mAb Against RA and Psoriasis
  
• AbbVie Expands Galapagos Collaboration to Include Crohn's Disease